BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Nov 10, 2014
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 11/7 cls
Aeterna Zentaris Inc. (TSX:AEZ; NASDAQ:AEZS) H.C. Wainwright Swayampakula Ramakanth Downgrade Neutral (from buy) -47% C$0.66
Ramakanth downgraded after FDA issued a complete response letter for an NDA for Macrilen macimorelin acetate (AEZS-130) to diagnose adult growth hormone deficiency (GHD). FDA requested the company conduct an additional confirmatory trial plus a QT study of the oral ghrelin-mimetic growth hormone secretagogue.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Wells Fargo Brian Abrahams Upgrade Outperform (from market perform) 2% $83.91
Abrahams also raised his target to $103-$107 from $72-$76 on growing sales of Vimizim elosulfase alfa and upcoming opportunities to present clinical data for multiple drug candidates in 2015....

Read the full 832 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >